Birmingham, West Midlands -- (SBWIRE) -- 01/23/2014 -- Value Penny Stocks issues special report on Generex Biotechnology Corporation (OTCMKTS:GNBT), Vringo, Inc. (NASDAQ:VRNG), Himax Technologies, Inc. (ADR) (NASDAQ:HIMX), Cell Therapeutics Inc (NASDAQ:CTIC).
Generex Biotechnology Corporation (OTCMKTS:GNBT) ended its recent business day with the gain of 3.78% and closed at the price of $0.0467 after opening at $0.05. The stock traded during its last trading session with the total volume of 16.54 million shares, as compared to its average volume of 6.09 million shares. Generex Biotechnology Corporation, a development stage company, is engaged in the research, development, and commercialization of drug delivery systems and technologies for metabolic and immunological diseases.
Will GNBT Continue To Move Higher? Find Out Here
Vringo, Inc. (NASDAQ:VRNG) remained among the day advancers and traded with volume of 16.59 million shares in the last session, as compared to average volume of 1.25 million shares. In comparison with 52 week range of $2.61 - $4.14, it faced lowest price of $3.07 during the last trading session whereas its day highest price was $4.14. The company’s total market capitalization is $320.52 billion, along with 81.13 million shares outstanding. Vringo, Inc., together with its subsidiaries, engages in the innovation, acquisition, licensing, and protection of intellectual property worldwide. Its intellectual property portfolio consists of approximately 500 patents and patent applications covering telecom infrastructure, Internet search, and mobile technologies.
Why Should Investors Buy VRNG After The Recent Gain? Just Go Here and Find Out
Himax Technologies, Inc. (ADR) (NASDAQ:HIMX) showed 16.23 million shares in volume during the last trading session, while the average trading volume remained 8.30 million shares. The stock kicked off its trading session at $14.20 and closed at $14.80 after mounting 7.01%. Himax Technologies, Inc. designs, develops, and markets semiconductors for flat panel displays. The company operates in two segments, Driver IC and Non-Driver Products. Its principal products include display drivers and timing controllers for large-sized thin film transistor liquid crystal display (TFT-LCD) panels that are used in desktop monitors, notebook computers, and televisions.
For How Long HIMX will Fight for Profitability? Read This Trend Analysis report
Cell Therapeutics Inc (NASDAQ:CTIC) stock traded during its last trading session with the total traded volume of 14.62 million shares versus its average volume of 5.15 million shares. The company opened its trade at the price of $4.11 and its closing price was $4.01 after losing -4.75% for the day. Cell Therapeutics, Inc. acquires, develops, and commercializes treatments for cancer. The company primary focuses on the commercialization of PIXUVRI, an aza-anthracenedione derivative, which is in Phase III clinical trials for the treatment of multiply relapsed or refractory aggressive non-Hodgkin lymphoma.
Will CTIC Get Buyers Even After The Recent Rally? Find Out Here
About Value Penny Stocks:
Value Penny Stocks was made by Two Active traders, Steve and Wilson, whom have made a platform for traders in order to provide traders the #1 Penny Stock Newsletter which actually gives value to your money and makes your portfolio full of profits. We concentrate on small cap stocks that trade on NYSE, NASD, AMEX, OTCBB, and OTC exchanges. These are usually stocks that will trade under $5 a share and offer the utmost potential profit on your short or long term investment. We also devote ourselves to understanding the overall market situations and use this knowledge in order to gain a better perception during our stock picking decisions.
We at ValuePennyStocks.com are engaged in the business of marketing and advertising companies. All content on our website is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. Neither the information presented nor any statement or expression of opinion, or any other matter herein, directly or indirectly constitutes a solicitation of the purchase or sale of any securities.
Please Read Our Full Disclaimer at: http://www.valuepennystocks.com/disclaimer/
Copyright © 2005-2014 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-593-5640 (International)